Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174226 · ClinicalTrials.gov registry record · Phase 2
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 241
- Enrollment target
NCT00174226 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 241 participants.
The verdict
NCT00174226, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 241 participants
- Enrollment target
Study Summary
Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
Interventions
- DRUG Atomoxetine
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174226
The ClinicalTrials.gov registry entry for NCT00174226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atomoxetine is the first listed.
NCT00174226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174226 about?
NCT00174226 is a clinical study titled "Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar". Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
What is the current status of trial NCT00174226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2004-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00174226?
The interventions under investigation include: Atomoxetine (DRUG), Buspirone (DRUG).
Who is sponsoring clinical trial NCT00174226?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.